Gene · 7357
Papers2,116
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 2,116
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Sphingomyelin Depletion Inhibits CXCR4 Dynamics and CXCL12-Mediated Directed Cell Migration in Human T Cells. | Front Immunol | 2022 | 35903108 | PubTator, text mining | PubMed |
| Ceramide/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer's Disease and Other Neurodegenerative Diseases. | Int J Mol Sci | 2022 | 35897658 | PubTator, text mining | PubMed |
| The expression of Phase II drug-metabolizing enzymes in human B-lymphoblastoid TK6 cells. | J Environ Sci Health C Toxicol Carcinog | 2022 | 35895929 | PubTator, text mining | PubMed |
| GCase Enhancers: A Potential Therapeutic Option for Gaucher Disease and Other Neurological Disorders. | Pharmaceuticals (Basel) | 2022 | 35890122 | PubTator, text mining | PubMed |
| Ceramide and Sphingosine-1-Phosphate in Neurodegenerative Disorders and Their Potential Involvement in Therapy. | Int J Mol Sci | 2022 | 35887154 | PubTator, text mining | PubMed |
| α-Synuclein Conformational Plasticity: Physiologic States, Pathologic Strains, and Biotechnological Applications. | Biomolecules | 2022 | 35883550 | PubTator, text mining | PubMed |
| Identifying Differential Expression Genes and Prognostic Signature Based on Subventricular Zone Involved Glioblastoma. | Front Genet | 2022 | 35873494 | PubTator, text mining | PubMed |
| Therapeutic Strategies For Tay-Sachs Disease. | Front Pharmacol | 2022 | 35865957 | PubTator, text mining | PubMed |
| Neuronal activity induces glucosylceramide that is secreted via exosomes for lysosomal degradation in glia. | Sci Adv | 2022 | 35857503 | PubTator, text mining | PubMed |
| Recent Progress in the Development of Opaganib for the Treatment of Covid-19. | Drug Des Devel Ther | 2022 | 35855741 | PubTator, text mining | PubMed |
RSPO1-mutated keratinocytes from palmoplantar keratoderma display impaired differentiation, alteration of cell-cell adhesion, EMT-like phenotype and invasiveness properties: implications for squamous cell carcinoma susceptibility in patients with 46XX disorder of sexual development. | Orphanet J Rare Dis | 2022 | 35854363 | PubTator, text mining | PubMed |
| Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease. | Drugs | 2022 | 35852784 | PubTator, text mining | PubMed |
| Development of a Novel Sphingolipid Signaling Pathway-Related Risk Assessment Model to Predict Prognosis in Kidney Renal Clear Cell Carcinoma. | Front Cell Dev Biol | 2022 | 35846357 | PubTator, text mining | PubMed |
| Immunolipidomics Reveals a Globoside Network During the Resolution of Pro-Inflammatory Response in Human Macrophages. | Front Immunol | 2022 | 35844525 | PubTator, text mining | PubMed |
| Structural basis for acyl chain control over glycosphingolipid sorting and vesicular trafficking. | Cell Rep | 2022 | 35830800 | PubTator, text mining | PubMed |
| GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review. | Int J Mol Sci | 2022 | 35806376 | PubTator, text mining | PubMed |
| In situ glucosylceramide synthesis and its pharmacological inhibition analysed in cells by 13 C5 -sphingosine precursor feeding and mass spectrometry. | FEBS Lett | 2022 | 35796054 | PubTator, text mining | PubMed |
| Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study. | Mol Genet Metab Rep | 2022 | 35782623 | PubTator, text mining | PubMed |
| Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3. | Mol Genet Metab Rep | 2022 | 35782609 | PubTator, text mining | PubMed |
| The Endless Wars: Severe Fever With Thrombocytopenia Syndrome Virus, Host Immune and Genetic Factors. | Front Cell Infect Microbiol | 2022 | 35782112 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7357/papers?page=19